Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 3
2000 7
2001 5
2002 14
2003 25
2004 40
2005 53
2006 62
2007 79
2008 57
2009 51
2010 62
2011 51
2012 34
2013 27
2014 26
2015 20
2016 16
2017 13
2018 14
2019 9
2020 14
2021 11
2022 6
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

610 results
Results by year
Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Morley LC, et al. Cochrane Database Syst Rev. 2017 Nov 29;11(11):CD003053. doi: 10.1002/14651858.CD003053.pub6. Cochrane Database Syst Rev. 2017. PMID: 29183107 Free PMC article. Review.
MAIN RESULTS: We assessed the interventions metformin, clomiphene citrate, metformin plus clomiphene citrate, D-chiro-inositol, rosiglitazone and pioglitazone. We compared these with each other, placebo or no treatment. ...There was no clear evidence of a difference in mis …
MAIN RESULTS: We assessed the interventions metformin, clomiphene citrate, metformin plus clomiphene citrate, D-chiro-inositol, rosiglita …
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group. Kahn SE, et al. N Engl J Med. 2006 Dec 7;355(23):2427-43. doi: 10.1056/NEJMoa066224. Epub 2006 Dec 4. N Engl J Med. 2006. PMID: 17145742 Free article. Clinical Trial.
The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin. Glyburide was associated with a lower risk of cardiovascular events (including congestive heart failure) than was ro …
The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazon …
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
Nissen SE, Wolski K. Nissen SE, et al. N Engl J Med. 2007 Jun 14;356(24):2457-71. doi: 10.1056/NEJMoa072761. Epub 2007 May 21. N Engl J Med. 2007. PMID: 17517853 Free article.
BACKGROUND: Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. ...Despite these limitations, patients and providers should consider the potential for serious advers …
BACKGROUND: Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity …
Rosiglitazone for type 2 diabetes mellitus.
Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Richter B, et al. Cochrane Database Syst Rev. 2007 Jul 18;2007(3):CD006063. doi: 10.1002/14651858.CD006063.pub2. Cochrane Database Syst Rev. 2007. PMID: 17636824 Free PMC article. Review.
MAIN RESULTS: Eighteen trials which randomised 3888 people to rosiglitazone treatment were identified. Longest duration of therapy was four years with a median of 26 weeks. ...New data on raised fracture rates in women reveal extensive action of rosiglitazone in var …
MAIN RESULTS: Eighteen trials which randomised 3888 people to rosiglitazone treatment were identified. Longest duration of therapy wa …
Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
Nissen SE, Wolski K. Nissen SE, et al. Arch Intern Med. 2010 Jul 26;170(14):1191-1201. doi: 10.1001/archinternmed.2010.207. Arch Intern Med. 2010. PMID: 20656674 Review.
STUDY SELECTION: The study included all randomized controlled trials of rosiglitazone at least 24 weeks in duration that reported CV adverse events. ...The current findings suggest an unfavorable benefit to risk ratio for rosiglitazone....
STUDY SELECTION: The study included all randomized controlled trials of rosiglitazone at least 24 weeks in duration that reported CV …
Effect of rosiglitazone on circulating malondialdehyde (MDA) level in diabetes based on a systematic review and meta-analysis of eight clinical trials.
Majidi Z, Hosseinkhani S, Amiri-Dashatan N, Emamgholipour S, Tutunchi S, Hashemi J, Ghorbani F, Koushki M. Majidi Z, et al. J Investig Med. 2021 Mar;69(3):697-703. doi: 10.1136/jim-2020-001588. Epub 2020 Dec 22. J Investig Med. 2021. PMID: 33408159 Review.
Patients with type 2 diabetes have high levels of malondialdehyde (MDA), and clinical data suggest a reducing effect of rosiglitazone (RSG) on the level of MDA in these patients. However, the results of available studies on the level of MDA in RSG-treated patients are not …
Patients with type 2 diabetes have high levels of malondialdehyde (MDA), and clinical data suggest a reducing effect of rosiglitazone …
Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Bundhun PK, Janoo G, Teeluck AR, Huang F. Bundhun PK, et al. BMC Pharmacol Toxicol. 2017 Oct 23;18(1):66. doi: 10.1186/s40360-017-0175-0. BMC Pharmacol Toxicol. 2017. PMID: 29058622 Free PMC article. Review.
In this analysis, we aimed to systematically compare the adverse drug events which were observed with the use of vildagliptin versus pioglitazone or rosiglitazone respectively. METHODS: Online databases were searched for studies comparing vildagliptin with pioglitazone/ …
In this analysis, we aimed to systematically compare the adverse drug events which were observed with the use of vildagliptin versus pioglit …
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
TODAY Study Group; Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F. TODAY Study Group, et al. N Engl J Med. 2012 Jun 14;366(24):2247-56. doi: 10.1056/NEJMoa1109333. Epub 2012 Apr 29. N Engl J Med. 2012. PMID: 22540912 Free PMC article. Clinical Trial.
Rates of failure were 51.7% (120 of 232 participants), 38.6% (90 of 233), and 46.6% (109 of 234) for metformin alone, metformin plus rosiglitazone, and metformin plus lifestyle intervention, respectively. Metformin plus rosiglitazone was superior to metformin alone …
Rates of failure were 51.7% (120 of 232 participants), 38.6% (90 of 233), and 46.6% (109 of 234) for metformin alone, metformin plus rosi …
Rosiglitazone causes endothelial dysfunction in humans.
Perampaladas K, Gori T, Parker JD. Perampaladas K, et al. J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):260-5. doi: 10.1177/1074248411425490. Epub 2011 Nov 3. J Cardiovasc Pharmacol Ther. 2012. PMID: 22053074 Clinical Trial.
METHODS: In this double-blind, randomized, placebo-controlled study, 44 participants were randomized to placebo, rosiglitazone (4 mg twice daily), transdermal GTN (0.6 mg/h), or both GTN and rosiglitazone. ...Neither rosiglitazone nor GTN treatment modified t …
METHODS: In this double-blind, randomized, placebo-controlled study, 44 participants were randomized to placebo, rosiglitazone (4 mg …
610 results

Searches related to "rosiglitazone"